SARS-CoV-2 recombinant spike protein + Advax-SM adjuvant

BIOLOGICAL5 trials

Sponsors

Cinnagen

Conditions

COVID-19Covid19

Phase 2

Phase II Clinical Trial of CinnaGen COVID-19 Vaccine (SpikoGen)

CompletedNCT04944368

CinnagenCovid19

Start: 2021-05-30End: 2021-12-30Updated: 2022-10-13

Phase 3

Phase III Clinical Trial of CinnaGen COVID-19 Vaccine (SpikoGen)

CompletedNCT05005559

CinnagenCovid19

Start: 2021-08-07End: 2022-03-10Updated: 2022-10-13

Immunogenicity and Safety of a Booster Dose of the SpikoGen COVID-19 Vaccine

CompletedNCT05175625

CinnagenCOVID-19

Start: 2021-12-15End: 2022-06-20Updated: 2022-10-14

Immunogenicity and Safety of the SpikoGen COVID-19 Vaccine in Children Aged 5 to <12 Years and 12 to <18 Years Compared With Adults Aged 18 to 40 Years

CompletedNCT05231590

CinnagenCOVID-19

Start: 2022-02-23End: 2022-09-30Updated: 2022-10-17

Unknown Phase

Immunogenicity and Safety of a Booster Dose of the SpikoGen Vaccine in Kidney Transplant Recipients After Two Doses of Sinopharm Vaccine

CompletedNCT05285384

CinnagenCOVID-19

Start: 2022-02-04End: 2022-03-30Updated: 2023-08-31